Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldafermin - NGM Biopharmaceuticals

Drug Profile

Aldafermin - NGM Biopharmaceuticals

Alternative Names: M52; NGM-282

Latest Information Update: 02 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Recombinant proteins
  • Mechanism of Action FGF19 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Type 2 diabetes mellitus
  • Phase I/II Constipation

Most Recent Events

  • 08 Nov 2019 NGM Biopharmaceuticals initiates a phase I trial in healthy volunteers in USA (SC) (NCT04179630)
  • 07 Oct 2019 Interim efficacy, safety and pharmacodynamics data from a phase IIb ALPINE 2/3 trial in non-alcoholic steatohepatitis released by NGM Biopharmaceuticals
  • 10 Apr 2019 Efficacy, pharmacodynamic and adverse events data from a phase II trial in Primary sclerosing cholangitis presented at the International Liver Congress 2019 (ILC-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top